Fujifilm will install payload and linker-payload manufacturing equipment, including reaction vessels, a filtration dryer and a preparative HPLC system, at the Hirono plant in Fukushima. The facility will also add a laboratory for process and analytical-method development, with operations scheduled to begin in 2028, enabling Fujifilm's one-stop domestic ADC CDMO service.
Shikoku Chuken will build a new headquarters facility on land adjacent to its existing headquarters in Ayagawa, Kagawa. The facility will expand research and development using clinical specimens and testing data collected from across Shikoku, along with corporate planning, information processing and administrative functions; operations are scheduled to begin in January 2028.
Olympus has completed the new B Building at its Nagano site in Tatsuno, Nagano, consolidating development and manufacturing functions and establishing a production base for key medical-device components. Construction began in February 2025, with full operation targeted for FY2026; the building has 17,665 sqm of total floor area and a total construction cost of approximately ¥18 billion.
JGC Holdings completed the UT3 biopharmaceutical active pharmaceutical ingredient facility for Chugai Pharmaceutical Industry at its Utsunomiya plant in May 2026. The four-story facility supports clinical-trial manufacturing through initial commercial production and includes continuous-production capabilities, solar panels and other environmental features; it was handed over on May 14, 2026.
Lion has approved construction of a new pharmaceutical plant through its wholly owned Vietnamese subsidiary Merap Lion. The facility will produce prescription and over-the-counter solid-dose medicines, including tablets and granules, with operations planned to begin in the second half of 2030.
Tsumura will build a new QC building and hazardous-materials warehouse at its Ibaraki Plant in Ami, Ibaraki, to strengthen quality-testing capacity and business continuity for its kampo pharmaceutical products. Construction costs approximately ¥7 billion, designed and built by Kajima Corporation, with completion planned for mid-April 2028.
Orthopedic medical device maker Nakashima Health Force will relocate its head office and factory to a new site in the Iwata district of Akaiwa City, Okayama Prefecture, investing approximately JPY 10 billion. The new facility will triple floor space versus the current plant, adding labor-saving/automation equipment and metal 3D printers, plus solar power, backup generators and water tanks for disaster resilience.
Pharma Foods International's consolidated subsidiary Meiji Yakuhin will build a new plant at Mizuhashi, Toyama City, with a board resolution on June 16, 2025. The new plant (13,109 sqm floor area, steel-frame, 3 stories) covers formulation, packaging and liquid-medicine lines, funded via a syndicated loan guaranteed by Pharma Foods International. Investment is JPY12.5 billion, with construction planned to start July 2026 and operations targeted for July 2028.
Sanyu Seisakusho has started operations at a new facility called Integra Center, which serves as a hub for assembly operations and warehouse functions to build a more stable production system. The company's core business is precision assembly for medical analysis equipment, though the announcement itself does not explicitly name that product line; financial details were not disclosed.
Kobayashi Pharmaceutical's wholly-owned subsidiary Sendai Kobayashi Pharmaceutical has begun full operation of a new pharmaceutical plant at the Sendai Kita Core Industrial Park in Taiwa-cho, Miyagi Prefecture. The facility, built to PIC/S GMP international standards with an investment of about JPY 26 billion, will produce liquid bandages, eye drops, and topical anti-inflammatory products, with total annual capacity of about 35 million units across all products.
Seed Co., a contact lens manufacturer, disclosed a partial change to the previously announced acquisition of fixed assets related to the second-phase construction of Building No. 4 at its Konosu Research Center. Specific revised terms were not detailed in the available text.
Dental materials maker GC Corporation is constructing a new biomaterials factory at its Fuji-Oyama plant site in Oyama Town, Shizuoka Prefecture, to expand production of bone graft materials and resorbable membranes. Chiyoda Ex-One Engineering is handling design and EPC construction with partners Kajima Corporation, Techno Ryowa, and Kandenko; construction began in June 2026 with completion targeted by November 30, 2027.
The Japan Blood Products Organization announced a plan to strengthen its production base for plasma-derived products, centred on building a new manufacturing plant on newly acquired land in Chitose, Hokkaido, at a scale of about JPY200 billion. The plan also refurbishes its two existing domestic sites (Chitose, Hokkaido and Fukuchiyama, Kyoto), doubling current plasma processing capacity. Japan's self-sufficiency rate for these products fell from near 100% in FY2015 to 59.4% in FY2025, and the expansion is aimed at restoring domestic supply.
Showing 1–13 of 13